Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Shareholders might have noticed that Redcare Pharmacy NV (ETR:RDC) filed its second-quarter result this time last week. The early response was not positive, with shares down 7.1% to €97.65 in the past week. It was an okay result overall, with revenues coming in at €709m, roughly what the analysts had been expecting. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the current consensus from Redcare Pharmacy's nine analysts is for revenues of €2.98b in 2025. This would reflect a solid 11% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 63% to €0.63. Yet prior to the latest earnings, the analysts had been forecasting revenues of €2.98b and losses of €1.03 per share in 2025. Although the revenue estimates have not really changed Redcare Pharmacy'sfuture looks a little different to the past, with a very promising decrease in the loss per share forecasts in particular.

See our latest analysis for Redcare Pharmacy

The average price target held steady at €164, seeming to indicate that business is performing in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Redcare Pharmacy at €214 per share, while the most bearish prices it at €82.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of Redcare Pharmacy'shistorical trends, as the 24% annualised revenue growth to the end of 2025 is roughly in line with the 24% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 4.7% per year. So it's pretty clear that Redcare Pharmacy is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Redcare Pharmacy going out to 2027, and you can see them free on our platform here.

It might also be worth considering whether Redcare Pharmacy's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.